Celldex Therapeutics
CLDX
162 hedge funds and large institutions have $917M invested in Celldex Therapeutics in 2015 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 68 increasing their positions, 40 reducing their positions, and 43 closing their positions.
70% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 40
13% less funds holding
Funds holding: 186 → 162 (-24)
45% less call options, than puts
Call options by funds: $9.58M | Put options by funds: $17.5M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
53% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 43
58% less capital invested
Capital invested by funds: $2.18B → $917M (-$1.27B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$36.3M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$18.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$11.3M |
| 4 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$9.77M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$8.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TimesSquare Capital Management
New York
|
-$47.3M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$27M |
| 3 |
Bank of New York Mellon
New York
|
-$21.2M |
| 4 |
CCM
Consonance Capital Management
New York
|
-$19M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$12.9M |
CLDX Hedge Fund Activity: Q3 2015 in Review
162 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q3 2015, worth a combined $917M — down 58% from $2.18B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of CLDX and 20 opened new positions — a net loss of 23 holders — while 40 trimmed existing stakes and 68 added.
The largest buyer was Redmile Group, adding an estimated $36.3M. The largest seller was TimesSquare Capital Management, exiting entirely with an estimated $47.3M sold.
- 162 institutional investors held Celldex Therapeutics (CLDX) as of Q3 2015, down from 186 in Q2 2015.
- Funds reported $917M of Celldex Therapeutics stock for Q3 2015, down 58% quarter-over-quarter.
- 20 funds opened new Celldex Therapeutics positions in Q3 2015 and 43 closed out, a net change of -23 holders.
- The largest Celldex Therapeutics buyer in Q3 2015 was Redmile Group, an estimated $36.3M added.
- The largest Celldex Therapeutics seller in Q3 2015 was TimesSquare Capital Management, an estimated $47.3M sold.
Based on aggregated 13F filings for Q3 2015.